All Stories

  1. What do we know about health technology assessment (HTA) in Africa?
  2. Bortezomib use and outcomes for the treatment of multiple myeloma
  3. What do we need to know? Data sources to support evidence-based decisions using health technology assessment in Ghana
  4. Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: What do the guidelines recommend?
  5. Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process
  6. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia
  7. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities
  8. Longitudinal impact of the Women’s Health Initiative study on hormone therapy use in Australia
  9. Does consumer medicines interest reflect medicines use? An observational study comparing medicines call center queries with medicines use
  10. Medicine use during acute and chronic postinjury periods in whiplash-injured individuals
  11. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life
  12. Forecasting the amount and cost of medicine to treat type 2 diabetes mellitus in Nepal using knowledge on medicine usage from a developed country
  13. Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit
  14. Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib
  15. Correction to: Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014
  16. Use of complementary and alternative medicines in people with depression and central obesity: Findings from a Tai Chi and Qigong study
  17. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014
  18. Cost saving with a GP-led integrated health service delivery model for complex chronic disease: an optimal Beacon practice
  19. Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose
  20. More needs to be spent on hepatitis C treatment, not less
  21. Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia
  22. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX)
  23. Impact of a general practitioner-led integrated model of care on the cost of potentially preventable diabetes-related hospitalisations
  24. The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition
  25. Opioid analgesic use in Australia and The Netherlands: a cross-country comparison
  26. Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting
  27. International trends in clozapine use: a study in 17 countries
  28. Prescribing patterns of analgesics and other medicines by dental practitioners in Australia from 2001 to 2012
  29. The impact of clozapine on hospital use: a systematic review and meta-analysis
  30. Triptan use in Australia 1997-2015: A pharmacoepidemiological study
  31. Forecasting the quantity and cost of medicines to treat non-communicable diseases in low- and middle-income countries: Applying knowledge on medicine use from developed countries
  32. Use of Healthcare Services by Patients with Non-Communicable Diseases in Nepal: A Qualitative Study with Healthcare Providers
  33. Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
  34. Prescribing patterns of dental practitioners in Australia from 2001 to 2012. Antimicrobials
  35. Ezetimibe: Use, costs, and adverse events in Australia
  36. Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital
  37. Case conference primary-secondary care planning at end of life can reduce the cost of hospitalisations
  38. Knowledge and attitudes of final year pharmacy students toward opioid substitution therapy
  39. Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland
  40. Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease
  41. Pharmacy workforce to prevent and manage non-communicable diseases in developing nations: The case of Nepal
  42. A Review of Medication Use as an Indicator of Human Health Impact in Environmentally Stressed Areas
  43. ‘Repeat’ prescriptions and antibiotic resistance: findings from Australian community pharmacy
  44. Understanding quality use of medicines in refugee communities in Australian primary care: a qualitative study
  45. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
  46. Consumer knowledge and perceptions about antibiotics and upper respiratory tract infections in a community pharmacy
  47. Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia
  48. Shift in disease burden from communicable to non-communicable diseases: aiming to achieve Universal Health Coverage in Nepal
  49. Clozapine in the community: Improved access or risky free-for-all?
  50. Increasing Clozapine Dispensing Trends in Queensland, Australia 2004–2013
  51. Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial
  52. Opioid analgesic prescribing in Australia: a focus on gender and age
  53. Multiple sclerosis disease modifying medicine utilisation in Australia
  54. Clozapine-induced myocarditis: Separating the wheat from the chaff
  55. Effects of decentralisation and health system reform on health workforce and quality-of-care in Indonesia, 1993-2007
  56. Quality of physical resources of health facilities in Indonesia: a panel study 1993-2007
  57. National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story
  58. Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia
  59. Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis
  60. A new model of integrated primary-secondary care for complex diabetes in the community: study protocol for a randomised controlled trial
  61. The prescribing of antiepileptic drugs for pregnant Australian women
  62. Psychiatric Drug Prescribing in Elderly Australians: Time for Action
  63. Australian National Trends in Stimulant Dispensing: 2002–2009
  64. Utilization of anti-Parkinson drugs in Australia: 1995-2009
  65. Prescribing trends in cognition enhancing drugs in Australia
  66. Marked increase in proton pump inhibitors use in Australia
  67. Patterns of Antipsychotic Medication Use in Australia 2002–2007
  68. Secondary Prevention of Osteoporosis in Australia
  69. Changing patterns of antiepileptic drug use in pregnant Australian women
  70. Anxiolytic, hypnotic and sedative medication use in Australia
  71. Antiepileptic drugs in Australia: 2002–2007
  72. In Australia are people born in other countries at higher risk of road trauma than locally born people?
  73. Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep
  74. Continuous intrafetal infusion of prostaglandin E2 prematurely activates the hypothalamo-pituitary-adrenal axis and induces parturition in sheep.
  75. Rebound increase in fetal breathing movements after 24-h prostaglandin E2 infusion in fetal sheep
  76. Prostaglandin E2 administered to fetal sheep increases the plasma concentration of adrenocorticotropin (ACTH) and the proportion of ACTH in low molecular weight forms.
  77. Prostaglandin E2 administered to fetal sheep increases the plasma concentration of adrenocorticotropin (ACTH) and the proportion of ACTH in low molecular weight forms
  78. Chronic administration of low doses of adrenocorticotropin to hypophysectomized fetal sheep leads to normal term labor
  79. Effect of Late Hypothalamo-Pituitary Disconnection on the Development of the HPA Axis in the Ovine Fetus and the Initiation of Parturition
  80. The metabolism and excretion of oestradiol-3β-d-glucuronide in rats